黑料吃瓜资源

Fighting cancer can seem like a deadly game of chance. While some patients may respond well to certain treatments, others might not be as fortunate. Doctors and scientists have long struggled to explain why. Now, 黑料吃瓜资源 (CSHL) Assistant Professor Katherine Alexander and University of Pennsylvania Professor Shelley Berger have found a possible source of this variability in clear cell renal cell carcinoma (ccRCC)鈥攖he most common kidney cancer diagnosed in adults.

Alexander has identified two different patterns of cellular structures known as nuclear speckles in kidney tumors. Even more exciting, Alexander鈥檚 research, conducted in Berger鈥檚 lab at the University of Pennsylvania, shows a potential correlation between speckle patterns and patient outcomes. Alexander explains:

鈥淲e found that different therapies are more or less effective depending on how the speckles look. This means potentially if a patient comes in with a normal or aberrant speckle state, they might be more responsive to one drug or another. Of course, more research needs to be done.鈥�

Discovered over 100 years ago, nuclear speckles are tiny cellular structures that reside in the nucleus. Here, they鈥檙e thought to intermingle with DNA and help regulate gene activity. Alexander鈥檚 research reveals that nuclear speckles have two different signatures in ccRCC: normal-like and aberrant. It鈥檚 a matter of positioning. Normal-like speckles tend to congregate toward the center of the nucleus. Aberrant speckles are more dispersed.

鈥淗ow these signatures affect patient outcomes remains a mystery for now,鈥� Berger says. 鈥淗owever, the search for answers may lead to more personalized treatments. This discovery offers a new starting point in ccRCC.鈥� Alexander adds:

鈥淚t鈥檚 the first suggestion that this would be potentially applicable to giving someone [diagnosed with ccRCC] one drug or another. That鈥檚 huge because cancer therapy has a lot of horrible side effects. To be able to tell a patient, 鈥榊our tumor looks like this, so we think this drug will work better than this drug,鈥� is something we really need.鈥�

The team didn鈥檛 just look at kidney cancer. They analyzed speckles in over 20 different types of cancers, from melanomas to breast cancer. However, only ccRCC showed a correlation between speckle patterns and patient outcomes. What makes this cancer special? Alexander鈥檚 findings point to HIF-2饾浖, a protein typically overactive in ccRCC. The Alexander lab aims to pursue this lead alongside other researchers at CSHL鈥檚 Cancer Center.

For now, Alexander continues to investigate the mystery of nuclear speckles鈥� role in cancer. Though she鈥檚 in uncharted territory, the object of her search is clear. Her work seeks to help stack the odds in cancer patients鈥� favor.

Written by: Luis Sandoval, Communications Specialist | [email protected] | 516-367-6826

Funding

National Institutes of Health, Penn Medicine, U.S. Department of Defense

Citation

Alexander, K. A., et al., 鈥淣uclear speckles regulate HIF-2伪 programs and correlate with patient survival in kidney cancer鈥�, Nature Cell Biology, January 2, 2025. DOI: